Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan

BACKGROUND: Lenvatinib was approved for use in unresectable hepatocellular carcinoma (uHCC) in Japan in 2018. Patients with diverse clinical characteristics receive lenvatinib treatment in clinical practice. Thus, it is crucial to evaluate the safety and effectiveness of lenvatinib in real-world cli...

Descripción completa

Detalles Bibliográficos
Autores principales: Furuse, Junji, Izumi, Namiki, Motomura, Kenta, Inaba, Yoshitaka, Katamura, Yoshio, Kondo, Yasuteru, Yabushita, Kazuhisa, Motoyoshi, Katsuaki, Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232401/
https://www.ncbi.nlm.nih.gov/pubmed/36602748
http://dx.doi.org/10.1007/s40801-022-00348-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10232401/
https://www.ncbi.nlm.nih.gov/pubmed/36602748
http://dx.doi.org/10.1007/s40801-022-00348-w

Ejemplares similares